Junhemeng Biopharmaceutical (Hangzhou) Co Ltd

09/10/2024 | Press release | Archived content

JHM Biopharmaceutical Raises Nearly CN¥350 million in Series B and B+ Financing

JHM Biopharmaceutical Raises Nearly CN¥350 million in Series B and B+ Financing

JHM Biopharmaceutical (Hangzhou) Co., Ltd. ("JHM") today announced that it has successfully completed a Series B+ financing round of over CN¥200 million, following its CN¥100 million Series B round in May.

The total funding raised has now reached close to CN¥350 million. SDIC Unity Capital led the Series B+ round, with participation from Hongsheng Capital, Oriza Holdings, and Soyoung Group. WinX Capital served as the exclusive financial advisor. The funds raised in this round will be primarily used to support the development of JHM's product pipeline, deepen its presence in health markets, and accelerate commercialization.

Junhemeng Biopharmaceutical (Hangzhou) Co Ltd published this content on September 10, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 29, 2026 at 11:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]